Skip to content
value.today
Aytu Bioscience logo

Aytu Bioscience

AYTU
$21 Mmarket cap on Oct 26, 2026+29.8% since Jan 2024
Compare
World rank
#24,234
Revenue
$58 M
For year ending June-2026
Net income
$-14 M
-24.8% margin
SEC filing
Employees
—

Aytu Bioscience in brief

Aytu Bioscience is a listed company in the Biotechnology industry, based in Denver, Colorado, USA. Its market value was $21 M on 26 October 2026, which makes it the 24,234th largest listed company in the world and the 4,150th largest in the USA on this site. In the year to June 2026 it had sales of $58 M and a net loss of $14 M. Joshua R. Disbrow is its chief executive. Its largest product and service lines by sales in 2026 were ADHD Portfolio (80%), E X X U A Portfolio (11%) and The Pediatric Portfolio (9%). Its shares trade under the symbol AYTU (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Aytu Bioscience timeline

4 events, 2007–2023
  1. 2007
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2015
  4. ✎
    Renamed Aytu Bioscience, Inc
    Formerly Rosewind CORP.
  5. 2021
  6. ✎
    Renamed Aytu Biopharma, Inc
    Formerly Aytu Bioscience, Inc.
  7. 2023
  8. 💰
    Record revenue of $107 million
    FY2023, the highest of the 9 years on record.

Events of Aytu Bioscience from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$28 M$56 M$83 M$111 M2020202120222023202420252026

World rank over time

▲ up 440 places since 2020
2020-01-01: #24698#24,69820202021-01-01: #18072#18,07220212022-01-07: #27387#27,38720222022-12-25: #30974#30,97420222023-07-30: #31502#31,50220232024-01-05: #29683#29,68320242026-03-08: #11733#11,73320262026-08-01: #21173#21,17320262026-10-14: #24136#24,13620262026-10-26: #24258#24,2582026

Rank in USA: #4,451 (Jan 2020) · #3,671 (Jan 2021) · #5,036 (Jan 2022) · #5,509 (Dec 2022) · #5,421 (Jul 2023) · #4,412 (Jan 2024) · #2,266 (Mar 2026) · #3,891 (Aug 2026) · #4,101 (Oct 2026) · #4,153 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.4×
Price / book
0.6×
Free cash flow yield
15.7%
Net margin (TTM)
-24.8%
Operating margin
-14.5%
Return on equity
-40.4%
Liabilities / assets
66.4%
Net debt
$-17M
Revenue growth
-13.3%
R&D / revenue
0.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2019: revenue $7M, net income $-27M$7MFY19Fiscal year ending Jun 2020: revenue $28M, net income $-14M$28MFY20Fiscal year ending Jun 2021: revenue $66M, net income $-58M$66MFY21Fiscal year ending Jun 2022: revenue $97M, net income $-109M$97MFY22Fiscal year ending Jun 2023: revenue $107M, net income $-17M$107MFY23Fiscal year ending Jun 2024: revenue $65M, net income $-16M$65MFY24Fiscal year ending Jun 2025: revenue $66M, net income $-14M$66MFY25Fiscal year ending Jun 2026: revenue $58M, net income $-14M$58MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2026$58M-13.3%$-8M$-14M-24.8%
Jun 2025$66M+1.8%$-8M$-14M-20.4%
Jun 2024$65M-39.3%$-2M$-16M-24.3%
Jun 2023$107M+11.1%$-17M$-17M-15.9%
Jun 2022$97M+47.3%$-110M$-109M-112.5%
Jun 2021$66M+137.5%$-59M$-58M-88.8%
Jun 2020$28M+277.5%$-21M$-14M-49.3%
Jun 2019$7M—$-17M$-27M-370.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2026$3M$0M$3M——
Jun 2025$-2M$0M$-2M——
Jun 2024$-1M$0M$-2M——
Jun 2023$-5M——$-5.11—
Jun 2022$-29M$0M$-29M$-74.01—
Jun 2021$-26M$2M$-28M$-3.48—
Jun 2020$-28M$0M$-28M$-3.01—
Jun 2019$-14M$0M$-14M$-3.48—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$58M
Net income, trailing 12 months
$-14M
RevenueNet income
Three months to Sep 2024: revenue $17M, net income $1M$17MSep ’24Three months to Dec 2024: revenue $16M, net income $1M$16MDec ’24Three months to Mar 2025: revenue $18M, net income $4M$18MMar ’25Three months to Jun 2025 (from the annual report): revenue $15M, net income $-20M$15MJun ’25Three months to Sep 2025: revenue $14M, net income $2M$14MSep ’25Three months to Dec 2025: revenue $15M, net income $-11M$15MDec ’25Three months to Mar 2026: revenue $12M, net income $-6M$12MMar ’26Three months to Jun 2026 (from the annual report): revenue $16M, net income $-0M$16MJun ’26

Latest quarter to Jun 2026: revenue $16M (+6.4% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Aytu Bioscience with the US Securities and Exchange Commission.

Annual results

Revenue
$58 M
Operating income
$-8 M
Net income
$-14 M

For year ending June-2026 · source: SEC filing

Balance sheet

Total assets
$105 M
Total liabilities
$70 M
Total equity
$35 M

As of June-2026

Top 36 institutional investors in Aytu Bioscience#

As of Sep 30, 2026
36 institutions held 3.7 M shares (about 34.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 32.8%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Aytu Bioscience
#InstitutionShares heldChange (shares)% heldValueFiled
1Nantahala Capital Management, LLC1,086,812-1,086,812 (-50.00%)10.00%$2 MNov 13, 2026
2Stonepine Capital Management, LLC964,900+51,979 (+5.69%)8.88%$2 MNov 13, 2026
3AWM Investment Company, Inc.619,5740 (0.00%)5.70%$1 MNov 13, 2026
4Vanguard Capital Management LLC261,1460 (0.00%)2.40%$1 MNov 13, 2026
5Crown Advisors Management, Inc.200,0000 (0.00%)1.84%$0 MNov 12, 2026
6Geode Capital Management, LLC123,670+30,023 (+32.06%)1.14%$0 MNov 6, 2026
7Renaissance Technologies LLC121,623+16,800 (+16.03%)1.12%$0 MNov 12, 2026
8Diadema Partners LP67,186-81,360 (-54.77%)0.62%$0 MNov 16, 2026
9Two Sigma Investments, LP65,513-39,813 (-37.80%)0.60%$0 MNov 16, 2026
10Dimensional Fund Advisors LP50,046+4,720 (+10.41%)0.46%$0 MNov 4, 2026
11Vanguard Fiduciary Trust Co48,144+1,096 (+2.33%)0.44%$0 MNov 13, 2026
12Northern Trust Corp27,9250 (0.00%)0.26%$0 MNov 16, 2026
13BlackRock, Inc.22,7930 (0.00%)0.21%$0 MNov 13, 2026
14Persistent Asset Partners Ltd17,166-20,818 (-54.81%)0.16%$0 MNov 13, 2026
15Citadel Advisors LLC12,678-36,736 (-74.34%)0.12%$0 MNov 16, 2026
16Daytona Street Capital LLC10,0000 (0.00%)0.09%$0 MOct 15, 2026
17Acadian Asset Management LLC9,437-800 (-7.81%)0.09%$0 MNov 9, 2026
18Nuveen, LLC2,101New0.02%$0 MNov 10, 2026
19Tower Research Capital LLC (TRC)1,541-691 (-30.96%)0.01%$0 MNov 16, 2026
20UBS Group AG895-1,482 (-62.35%)0.01%$0 MNov 10, 2026
21Osaic Holdings, Inc.4620 (0.00%)0.00%$0 MNov 12, 2026
22Royal Bank Of Canada379+1 (+0.26%)0.00%$0 MNov 16, 2026
23Jpmorgan Chase & Co188+34 (+22.08%)0.00%$0 MNov 12, 2026
24Wells Fargo & Company/mn1270 (0.00%)0.00%$0 MNov 16, 2026
25Morgan Stanley1250 (0.00%)0.00%$0 MNov 13, 2026
Show all 36: investors 26 to 36
Institutional investors 26 to 36 in Aytu Bioscience
#InstitutionShares heldChange (shares)% heldValueFiled
26Group One Trading LLC370 (0.00%)0.00%$0 MNov 10, 2026
27BNP Paribas Financial Markets230 (0.00%)0.00%$0 MNov 12, 2026
28Citigroup Inc18New0.00%$0 MNov 4, 2026
29Rockefeller Capital Management L.P.100 (0.00%)0.00%$0 MNov 13, 2026
30SBI Securities Co., Ltd.100 (0.00%)0.00%$0 MOct 22, 2026
31NewEdge Advisors, LLC3New0.00%$0 MNov 13, 2026
32Vision Financial Markets LLC20 (0.00%)0.00%$0 MOct 22, 2026
33Arax Advisory Partners20 (0.00%)0.00%$0 MNov 12, 2026
34Caitong International Asset Management Co., Ltd20 (0.00%)0.00%$0 MOct 29, 2026
35Jones Financial Companies Lllp10 (0.00%)0.00%$0 MNov 13, 2026
36Tsfg, LLC10 (0.00%)0.00%$0 MOct 23, 2026

Mutual funds holding Aytu Bioscience#

16 funds hold shares worth $1 M (about 3.4% of the company). Since their previous reports 4 added shares and 1 sold, selling $0 M net.
Mutual funds holding Aytu Bioscience
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.169,000$0 M1.6%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.92,146$0 M0.85%<0.01%+14%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC50,229$0 M0.46%<0.01%+13%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC11,929$0 M0.11%<0.01%+22%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC9,757$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP5,481$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP4,805$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP4,640$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP4,402$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,122$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP4,100$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP2,147$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP1,741$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP1,710$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC1,500$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC200$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 16 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Aytu Bioscience#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
22
since
$125 K$0Feb 2025: bought $20 K (1 trades), sold $0 (0 trades)Feb 25Jun 2025: bought $125 K (2 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Aytu Bioscience: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joshua R. DisbrowChief Executive Officer, DirectorGrant or award+30,000——237,203Form 4
filed Carl DockeryDirectorGrant or award+10,000——31,152Form 4
filed John Donofrio Jr.DirectorGrant or award+10,000——23,762Form 4
filed Abhinav JainDirectorGrant or award+10,000——29,500Form 4
filed Jarrett DisbrowChief Business OfficerGrant or award+15,000——76,568Form 4
filed Greg PyszczymukaChief Commercial OfficerGrant or award+20,000——56,102Form 4
filed Ryan J. SelhornChief Financial OfficerGrant or award+25,000——74,743Form 4
filed Vivian H. LiuDirectorGrant or award+10,000——29,825Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Aytu Bioscience#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
301,698
2.8% of shares · 11.65 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split ; 12.174-for-1 split

Trading halts

  • 2026-11-16 21:00 UTC, code T3, resumed 21:40 UTC

Fails to deliver

  • : 29 shares at $1.91
  • : 448 shares at $1.96
  • : 41 shares at $2.01
  • : 139 shares at $1.96
  • : 105 shares at $1.99

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Aytu Bioscience scorecard#

Passes 9 of the 21 checks that could be worked out: strongest in valuation (3 of 5), weakest in growth (1 of 5). Fiscal year 2026; market cap of Oct 26, 2026.

  • Valuation3 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Biotechnology's median of 8.7×.
    • ✓Free cash flow yield above 5%15.7%Free cash flow is 15.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 5
    • ✗Revenue grew in the newest year-13.3%Revenue down 13.3% in fiscal 2026.
    • ✗Revenue up more than 5% a year over three years-18.8%-18.8% a year over the three years to fiscal 2026.
    • ✗Faster growth over three years than its peers' median-18.8%-18.8% a year against Biotechnology's median of 12.9% (181 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✓Net income higher than five years earlier-$14 M-$14 M in fiscal 2026 against -$58 M in 2021.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2026.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • ✓Operating margin above its peers' median-14.4%-14.4% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-52.5%-52.5% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-14.4%-14.4% in fiscal 2026 against -15.9% in 2023.
  • Financial health3 of 6
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.13 at the end of fiscal 2026.
    • ✓Debt below equity0.3×Debt to equity 0.26 at the end of fiscal 2026.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $17 M at the end of fiscal 2026.
    • ✗Operating income covers interest five times-4.4×Operating income -4.4 times interest in fiscal 2026.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2026.
    • ✗Altman Z-score outside the distress zone-4.09Z-score -4.09 (distress zone) for fiscal 2026.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2026#

Worked out from Aytu Bioscience's statements, beside the median of Biotechnology.

Aytu Bioscience: main financial ratios in 2026
Ratio2026Median of peers
Operating margin-14.5%-60.5%
Net margin-24.8%-68.9%
Return on equity-52.5%-61.0%
Revenue growth, 3 years a year-18.8%12.9%
Revenue growth-13.3%15.8%
Debt to equity0.26×0.26×

4of 9on the Piotroski tests of financial strength

  • Revenue fell 13.3% against the year before.
  • Net loss of $14 million, the 16th loss-making year in a row.
  • Operating income covers the interest bill only -4.4 times.
  • More cash than debt: net cash of $17 million.

Aytu Bioscience: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Aytu Bioscience: statements by fiscal year
PeriodTrendFY 2026to Jun 30, 2026FY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020FY 2019to Jun 30, 2019FY 2018to Jun 30, 2018FY 2017to Jun 30, 2017
Income statement
Revenue586665r1079766287.33.73.2
Cost of revenue212116r4144368.3r2.22.11.4
Gross profit374649r67522919———
Research and development01.32.8r4.113r5.61.7r0.60.21.0
Selling, general and administrative——————35191817
Selling and marketing232122r41393011———
General and administrative191720r29312620———
Operating expenses455451r84162r8840r242323
Operating income−8.3−7.8−1.6r−17−110r−59−21r−17−20−20
Interest expense and finance costs1.93.75.1r5.00.9—2.60.50.72.5
Other non-operating income (expense)0.7−0.50.9r0.01.0r0.87.5r−109.5−2.4
Income before tax−14−14−10r−17−109r−58−14———
Income tax0.00.42.1r0−0.10.30000
Income from continuing operations−14−14−13———————
Income from discontinued operations00.6−3.3———————
Net income including minority interests———−17−109r−58−14———
Net income attributable to shareholders−14−14−16−17−109r−58−14r−27−10−23
Earnings per share, basic-1.16-2.16-2.86-5.11-74.01r-3.48-3.01r-3.48-15.31-48.30
Earnings per share, diluted———-5.11-74.01r-3.48-3.01r-3.48-15.31-48.30
Shares, weighted average (basic)126.35.53.31.5r17————
Shares, weighted average (diluted)———3.31.5r174.5r7.80.70.5
Balance sheet
Cash and cash equivalents26312023195048r117.00.8
Short-term investments—————————0
Receivables233124r2922285.6r1.70.60.5
Inventory6.91112r12111610.0r1.41.31.3
Other current assets5.85.66271r0.61.05.7r0r0.40.3
Current assets627962736010575r159.53.0
Property, plant and equipment0.40.50.71.83.05.10.30.20.20.6
Right-of-use (leased) assets0.91.10.82.13.33.60.6r0——
Goodwill———006628r0—0.2
Other intangible assets41425259718549r49r0.20.3
Non-current assets43455665r7816078r191212
Total assets105124118136138266153r352115
Accounts payable111110r13—1912r2.1r2.12.2
Debt due within a year1.91.91.90.10.1171.00——
Current liabilities556362696410929r5.43.43.6
Long-term debt9.1111115140.20———
Lease liabilities (non-current)0.91.00.60.82.12.60.7r0——
Non-current liabilities15422828——————
Total liabilities———9793r12858r287.611
Retained earnings−348−334−320−304−287r−178−120r−106−79−69
Shareholders' equity3519283944r13895r7.1134.0
Total equity———3944r13895———
Total liabilities and equity105124118136138266153r352115
Shares outstanding119.06.05.51.9r2713r181.80.0r
Cash-flow statement
Depreciation and amortization3.95.48.38.810r9.25.7r2.72.64.4
Share-based compensation0.70.62.4r6.05.23.61.1r1.00.6r2.5
Cash from operating activities3.3−1.9−1.4−5.1−29−26−28r−14−16−14
Capital expenditure−0.0−0.2−0.3—0−2.30−0.1−0.1−0.1
Intangible assets bought0−3.00——————−6.0
Cash from investing activities−0.0−2.6−0.3−0.1−3.2−2.8−5.7r−1.1−0.5−3.5
Debt issued01.913———0.60r0—
Debt repaid−1.9−1.9−16−0.1——————
Shares issued———16124566——0.7
Cash from financing activities−7.915−1.38.91.53071r192310
Change in cash−4.611−3.03.6−311.637r4.26.2−7.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Aytu Bioscience sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • ADHD Portfolio$46 M80%
  • E X X U A Portfolio$7 M11%
  • The Pediatric Portfolio$5 M8.9%
  • Product and Service, Other$0 M0.1%

Business segments

  • RX$58 M100%

Source: SEC annual report (XBRL data) · as of Jun 30, 2026

Executive pay at Aytu Bioscience#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2026
$845 K
Joshua R. Disbrow
Other top executives, average
$553 K
the CEO earned 1.5× this
$100 invested is now
$134
Aytu Bioscience: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2026Joshua R. Disbrow$845 K$855 K$553 K$134
2025Joshua R. Disbrow$884 K$867 K$462 K$136
2024Joshua R. Disbrow$928 K$919 K$548 K$183

Source: SEC proxy statement (Form DEF 14A) · as of Jun 30, 2026

Events at Aytu Bioscience#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 5 · Agreement ended 2 · New debt 2 · Unregistered share sale 1 · Shareholder rights changed 1 · Shareholder vote 3 · Results announced 10

Aytu Bioscience: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Agreement ended8-K
Results announced8-K
Material agreementUnregistered share saleShareholder rights changedResults announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Agreement ended8-K
Material agreementNew debt8-K
Acquisition or sale completedMaterial agreement8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officersResults announced8-K
Results announced8-K
Shareholder vote8-K
Material agreementNew debt8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Sep 22, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Aytu Bioscience
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2019$10 MPrivate placement after listing$10 to $50 million2equity, optionsSEC
Aug 2017$12 MPrivate placement after listing$10 to $50 million70equity, optionsSEC
May 2017$2 MPrivate placement after listingUnder $2 million16equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Aytu Bioscience#

$0 spent on lobbying the US Congress and federal agencies in 2025.

Lobbying, 2025
$0
#1,547 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$0

Lobbying firms hired in 2025

Dorsey & Whitney LLP

Aytu Bioscience: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$0—3
2025$0—4
2024$10 K—4
2023$20 K—5
2022$0—3
2021$30 K—4
2020$40 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Aytu BioPharma, Inc. (formerly known as Aytu BioScience, Inc.)” and “Aytu BioScience, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Aytu Bioscience#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $100 K a year.

Certified, FY2024
1
#2,004 among companies on value.today
Worker positions
1
Median wage offered
$100 K
a year, full-time
Applications filed
1
Aytu Bioscience: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Commercial Reporting and Analytics ManagerData Scientists1$100 K

Where: Denver, CO 1

Aytu Bioscience: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202411$100 K1
FY202111$68 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aytu BioPharma, Inc.

How Aytu Bioscience compares in Biotechnology

  • Market cap$21 M · higher than 18% of 726
  • Revenue$58 M · higher than 61% of 647
  • Net margin-24.8% · higher than 58% of 408
  • Revenue growth-13.3% · higher than 32% of 438
  • Price / sales0.4× · lower than 98% of 339
  • Price / book0.6× · lower than 90% of 534
  • FCF yield15.7% · higher than 99% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Aytu Bioscience🇺🇸$21 M—-24.8%-13.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending June-2026
Balance sheet:
As of June-2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Aytu Bioscience? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Aytu Bioscience's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Aytu Bioscience? Suggest a correction